Investigational drug · Phase 2
SYS6088
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced/Metastatic Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SYS6088"
First trial start
2026
Oct 3, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6088", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced/Metastatic Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6088" as an intervention, largest first.
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid TumorsNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07857135 · 140 participants (planned) · Start Oct 3, 2026 · Primary completion Feb 3, 2029
Drug: SYS6088; Regorafenib and 1 more · For: Advanced/Metastatic Solid Tumors
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced/Metastatic Solid Tumors
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- ADG126Phase 23 trials
Adagene Inc · Advanced/Metastatic Solid Tumors, Solid Tumor, Advanced Liver Cancers
- HRS-6719Phase 21 trial
Shandong Suncadia Medicine Co., Ltd. · Advanced/Metastatic Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.